文献速递消化道肿瘤放疗姑息放疗与转移瘤

在高流量机构与学术中心治疗的局部晚期胰腺癌患者的治疗策略与临床结局

Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers.
PubMed 文献 · Adv Radiat Oncol · 2018-11-09

利用美国国家癌症数据库分析10,139例局部晚期胰腺癌患者,高流量机构与学术中心治疗均与总生存改善显著相关(HR 0.84与0.94),放疗与多药化疗亦与总生存改善显著相关(HR 0.76与0.73),多药化疗是接受手术的显著预测因素(OR 1.29)。

要点

  • 高流量机构治疗与较低流量机构相比,中位总生存为14.3个月对11.2个月(P<.001)。
  • 学术中心治疗与非学术中心相比,中位总生存为12.1个月对10.8个月(P<.001)。
  • 多因素分析中放疗与多药化疗均与总生存改善显著相关(HR 0.76与0.73,均P<.001)。

核心结论

  • 研究结果支持放疗和多药化疗用于治疗局部晚期胰腺癌。
  • 作者认为,在缺乏前瞻性数据的情况下,这为在学术中心和高流量机构考虑使用多药化疗联合放疗治疗局部晚期胰腺癌提供了有力依据。

研究设计与样本

  • 使用美国国家癌症数据库获取10,139例局部晚期胰腺癌患者的数据。
  • 高流量机构定义为按各机构治疗患者数量排名前5%的机构。
  • 采用单因素和多因素Cox回归分析评估高流量机构、学术中心、多药化疗和放疗对总生存的影响。

主要发现

  • 患者中位年龄66岁(范围22-90岁),男性占50.1%,女性占49.9%。
  • 46.1%接受多药化疗,53.8%接受单药化疗,45.7%接受放疗,54.3%未接受放疗,5%接受手术切除。
  • 中位随访时间为48.8个月。
  • 多因素分析中,高流量机构治疗与学术中心治疗均与总生存改善显著相关,风险比分别为0.84(P<.001)和0.94(P=.004)。
  • 多因素分析中,接受放疗与多药化疗均与总生存改善显著相关(HR 0.76,P<.001;HR 0.73,P<.001)。

关键数值与推荐

  • 高流量机构治疗与低流量机构相比,中位总生存为14.3个月对11.2个月(P<.001)。
  • 学术中心治疗与非学术中心相比,中位总生存为12.1个月对10.8个月(P<.001)。

临床怎么用

  • 作者认为,在缺乏前瞻性数据的情况下,这为在学术中心和高流量机构考虑使用多药化疗联合放疗治疗局部晚期胰腺癌提供了有力依据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Locally advanced pancreatic cancer (LAPC) treatment has varying practice patterns with poor outcomes. We investigated treatment using single-agent chemotherapy and multiagent chemotherapy (MAC) with or without radiation therapy (RT) at high-volume facilities (HVFs) and academic centers (ACs). METHODS AND MATERIALS: The National Cancer Database was used to obtain data on 10,139 patients with LAPC. HVF was defined as the top 5% of facilities per number of patients treated at each facility. Univariate and multivariable (MVA) analysis Cox regressions were performed to identify the impact of HVF, AC, MAC, and RT on overall survival (OS). RESULTS: The median age of patients was 66 years (range, 22-90); 50.1% were male and 49.9% female. Of the patients, 46.1% received MAC, 53.8% received single-agent chemotherapy, 45.7% received RT, 54.3% did not receive RT, and 5% underwent surgical resection. The median follow-up was 48.8 months. On MVA, treatment at HVFs and ACs remained significantly associated with improved OS, with a hazard ratio (HR) of 0.84 (P < .001) and 0.94 (P = .004), respectively. The median OS for HVF treatment compared with low-volume facilities was 14.3 versus 11.2 months, respectively (P < .001). The median OS for AC treatment versus non-AC was 12.1 versus 10.8 months, respectively (P < .001). Additionally, on MVA, receipt of RT and MAC remained significantly associated with improved OS (HR: 0.76; P < .001; and HR: 0.73; P < .001, respectively). MVA for receipt of surgery showed that MAC is a significant predictor for receiving surgery (odds ratio: 1.29; P = .009). CONCLUSIONS: Our results build on a growing literature supporting RT and MAC in treating LAPC. Additionally, we believe that-in the absence of prospective data-this makes a strong case for considering MAC with RT at ACs and HVFs for treating LAPC.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. David JM, Kim S, Placencio-Hickok VR, et al. Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. Adv Radiat Oncol. 2018. PMID: 31011675. doi:10.1016/j.adro.2018.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。